<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605826</url>
  </required_header>
  <id_info>
    <org_study_id>33DA0404</org_study_id>
    <nct_id>NCT00605826</nct_id>
  </id_info>
  <brief_title>A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence</brief_title>
  <official_title>A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med Scandinavia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oceana Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Q-Med Scandinavia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used
      as an injectable bulking agent in the treatment of fecal incontinence. The study includes a
      6-month blinded sham-controlled phase, followed by an open-label phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in the sham control group will have the option to receive open-label treatment with
      NASHA/Dx after the blinded phase.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are Responder50.</measure>
    <time_frame>6 months after last blinded treatment</time_frame>
    <description>Proportion of subjects who achieve ≥ 50% reduction in the number of fecal incontinence episodes compared to baseline (Responder50).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who are Responder25.</measure>
    <time_frame>12 months after last blinded treatment</time_frame>
    <description>Proportion of subjects who achieve ≥ 25% reduction in the number of fecal incontinence episodes compared to baseline (Responder25).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of fecal incontinence episodes</measure>
    <time_frame>upto 36 months after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incontinence free days</measure>
    <time_frame>upto 36 months after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Incontinence Quality of Life Scale (FIQL).</measure>
    <time_frame>upto 36 months after last treatment</time_frame>
    <description>Fecal Incontinence Quality of Life Scale (FIQL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleveland Clinic Florida Incontinence Score (CCFIS).</measure>
    <time_frame>upto 36 months after last treatment</time_frame>
    <description>Cleveland Clinic Florida Incontinence Score (CCFIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months after last blinded treatment and upto 36 months after last treatmtent</time_frame>
    <description>Adverse events reported during the 6 month blinded phase of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded injection of NASHA/Dx Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Blinded sham injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NASHA/Dx Injectable Gel</intervention_name>
    <description>Injection of 4 x 1ml of NASHA/Dx Gel</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Injection</intervention_name>
    <description>Sham injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years of age, male or female

          -  Screening fecal incontinence severity score (CCFIS)

          -  Fecal incontinence episodes over a 14-day period

          -  Failed conservative treatment for fecal incontinence

        Exclusion Criteria:

          -  Complete external sphincter disruption

          -  Significant anorectal disease

          -  Anorectal surgery within the last 12 months prior to the study

          -  Active Inflammatory Bowel Disease (IBD)

          -  Immunodeficiency or receiving immunosuppressive therapy

          -  Malignancies in remission for less than 2 years prior to the study

          -  Bleeding disorders or receiving anticoagulant therapy

          -  Chemotherapy within the last 12 months prior to the study

          -  Prior Pelvic radiotherapy

          -  Women who are pregnant or breast-feeding, or women of childbearing potential not
             practicing adequate contraception or planning to stop such contraception within the
             first year of the study

          -  Women within one year post partum

          -  Participation in any other clinical study within 3 month prior to the study

          -  Hypersensitivity to hyaluronic acid containing products

          -  Other severe conditions or in other ways unsuitable to participate according to
             investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco, Center for Pelvic Physiology, Dept. of Surgery</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine, Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic, Department of Colon &amp; Rectal Surgery</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colon &amp; Rectal Surgery Associates</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's/Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorectal Surgical Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Research/Center for Colon Rectal Disease</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Klinik Mit Poliklinik, FAU Erlangen-Nurnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>910 54</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgmottagningen Universitetssjukhuset MAS</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgmottagningen, Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgkliniken, Uppsala Akademiska Sjukhus</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital, Department of Academic Surgery</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <last_update_submitted>July 13, 2011</last_update_submitted>
  <last_update_submitted_qc>July 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>John W Egan, Director, Medical Affairs &amp; Clinical Research</name_title>
    <organization>Oceana Therapeutics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

